发布求助
文献互助 智能选刊 最新文献

Clinical pharmacology and therapy最新文献

筛选
英文 中文
Fractional flow reserve assessment for guiding the strategy of endovascular treatment of patients with chronic coronary syndrome and multivessel coronary artery disease 用于指导慢性冠状动脉综合征和多支血管冠状动脉疾病患者血管内治疗策略的分数血流储备评估
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-41-44
E. L. Vartanyan, R.S. Polyakov, L. Dyachuk, D.V. Fetzer, Y. Arutyunova, N.A. Karanadze, M.A. Trukhanova, N. A. Mironov, S.T. Matskeplishvili
{"title":"Fractional flow reserve assessment for guiding the strategy of endovascular treatment of patients with chronic coronary syndrome and multivessel coronary artery disease","authors":"E. L. Vartanyan, R.S. Polyakov, L. Dyachuk, D.V. Fetzer, Y. Arutyunova, N.A. Karanadze, M.A. Trukhanova, N. A. Mironov, S.T. Matskeplishvili","doi":"10.32756/0869-5490-2023-4-41-44","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-41-44","url":null,"abstract":"To evaluate the impact of fractional flow reserve (FFR) assessment on the choice of the myocardial revascularization strategy in patients with ischemic heart disease and multivessel coronary artery disease and to compare the long-term outcomes of complete functional or anatomical revascularization.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal dosage regimen of Ranquilon® for patients with anxiety associated with neurasthenia and adaptation disorders: phase II clinical trial 针对神经衰弱和适应障碍相关焦虑症患者的兰喹隆®最佳剂量方案：II 期临床试验
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-36-40
O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko
{"title":"Optimal dosage regimen of Ranquilon® for patients with anxiety associated with neurasthenia and adaptation disorders: phase II clinical trial","authors":"O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko","doi":"10.32756/0869-5490-2023-4-36-40","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-36-40","url":null,"abstract":"To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of clinical pharmacology consultation into the obligatory medical insurance system 将临床药理咨询纳入强制性医疗保险制度
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-77-80
А. Fedorenko, A. Burbello, D.A. Sychev, M. Pokladova
{"title":"Implementation of clinical pharmacology consultation into the obligatory medical insurance system","authors":"А. Fedorenko, A. Burbello, D.A. Sychev, M. Pokladova","doi":"10.32756/0869-5490-2023-4-77-80","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-77-80","url":null,"abstract":"To determine the rationale for implementation of clinical pharmacology consultation into the Russian obligatory medical insurance system.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of antibodies to the M-type phospholipase A2 receptor in patients with primary membranous nephropathy 原发性膜性肾病患者体内的 M 型磷脂酶 A2 受体抗体的临床意义
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-45-50
P. Kakhsurueva, E. Kamyshova, I.N. Bobkova, E. Andreeva, O.A. Li
{"title":"Clinical significance of antibodies to the M-type phospholipase A2 receptor in patients with primary membranous nephropathy","authors":"P. Kakhsurueva, E. Kamyshova, I.N. Bobkova, E. Andreeva, O.A. Li","doi":"10.32756/0869-5490-2023-4-45-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-45-50","url":null,"abstract":"To evaluate the significance of circulating antibodies to the M-type phospholipase A2 receptor (anti-PLA2R) in the diagnosis of primary membranous nephropathy (MN) and the determination of the clinical features of the disease.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of real-world data for drug development 将真实世界的数据用于药物开发
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-16-23
A.S. Kolbin, R.R. Niyazov, V.V. Kalinichenko, S.V. Glagolev
{"title":"Use of real-world data for drug development","authors":"A.S. Kolbin, R.R. Niyazov, V.V. Kalinichenko, S.V. Glagolev","doi":"10.32756/0869-5490-2023-4-16-23","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-16-23","url":null,"abstract":"The use of real-world data (RWD) and real-world evidence (RWE) is an international trend in the modern healthcare system. In a review article, the authors highlight the use of RWD/RWE for drug development in the following categories: drug-drug interactions; dose selection in special populations such as patients with elimination organ dysfunction; dosing optimization in children; the use of quantitative clinical pharmacology in model-based drug development; use of RWE as a parallel data source to complement a randomized controlled trial to extend indications; RWD/RWE to create an external control group for rare diseases.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic renal failure in Fabry disease: the long-term survival on renal replacement therapy 法布里病的慢性肾衰竭：肾替代疗法的长期存活率
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-58-63
E. Tao, A. Moiseev, N. Bulanov, V. Sholomova, S. Moiseev
{"title":"Chronic renal failure in Fabry disease: the long-term survival on renal replacement therapy","authors":"E. Tao, A. Moiseev, N. Bulanov, V. Sholomova, S. Moiseev","doi":"10.32756/0869-5490-2023-4-58-63","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-58-63","url":null,"abstract":"To evaluate survival among patients with Fabry disease (FD) depending on the type of renal replacement therapy and to investigate the efficacy of dialysis screening in the early diagnosis of FD in relatives of probands.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nephrotic syndrome: ethiological factors and differential diagnosis 肾病综合征：病因和鉴别诊断
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-5-15
S. Moiseev, I.N. Bobkova, N. Chebotareva, N. Bulanov
{"title":"Nephrotic syndrome: ethiological factors and differential diagnosis","authors":"S. Moiseev, I.N. Bobkova, N. Chebotareva, N. Bulanov","doi":"10.32756/0869-5490-2023-4-5-15","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-5-15","url":null,"abstract":"Nephrotic syndrome (NS), characterized by proteinuria >3.5 g daily and hypoalbuminemia (± oedema and dyslipidemia) is one of the leading manifestations of various glomerular diseases, both primary and secondary (systemic autoimmune diseases, diabetes mellitus, amyloidosis, monoclonal gammapathy, malignancy, infections, drugs, etc). Kidney biopsy is usually required to establish the cause of NS in adult patients and to choose optimal treatment. In a review article, the authors discuss the most common ethiological factors of NS and its differential diagnosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypophosphatasia in adults: how not to overlook a rare disease? 成人低磷酸盐症：如何避免忽视罕见疾病？
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-64-72
S. Moiseev, N. Chebotareva, A. Moiseev, P. Novikov, V. Sholomova
{"title":"Hypophosphatasia in adults: how not to overlook a rare disease?","authors":"S. Moiseev, N. Chebotareva, A. Moiseev, P. Novikov, V. Sholomova","doi":"10.32756/0869-5490-2023-4-64-72","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-64-72","url":null,"abstract":"Hypophosphatasia (HPP) is a rare hereditary disease characterized by reduced activity of tissue-nonspecific alkaline phosphatase (TNSALP) encoded by ALPL gene, defective mineralization of bone (osteomalacia) and various musculoskeletal manifestations, such as bone deformity, teeth loss, recurrent fractures, chronic bone and muscle pain, reduced muscular strength, etc. Deficiency of TNSALP activity leads to the extracellular accumulation of its substrates, including inorganic pyrophosphate that inhibits bone mineralization. Homozygous and compound heterozygous mutations of the ALPL gene are associated with a lower TNSALP activity and HPP severity. However, heterozygous dominant negative variants can also result in clinical manifestations. The authors present two adult patients with HPP and discuss diverse clinical features of the disease and the efficacy of asfotase alpha, the human recombinant enzyme-replacement therapy that replaces deficient TNSALP. In adults and adolescents with pediatric-onset HPP, treatment with asfotase alfa was associated with improved functional abilities and health-related quality of life.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"148 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Features of myocardial infarction with ST segment elevation in patients with non-alcoholic liver steatosis and steatohepatitis 非酒精性脂肪肝和脂肪性肝炎患者心肌梗死伴 ST 段抬高的特征
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-51-57
V. A. Tretyakova, O. V. Ermilov, P. K. Alferov
{"title":"Features of myocardial infarction with ST segment elevation in patients with non-alcoholic liver steatosis and steatohepatitis","authors":"V. A. Tretyakova, O. V. Ermilov, P. K. Alferov","doi":"10.32756/0869-5490-2023-4-51-57","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-51-57","url":null,"abstract":"To evaluate the features of ST-segment elevation myocardial infarction (STEMI) in patients with two types of metabolic-associated fatty liver disease (MAFLD), that is, liver steatosis (LS) and steatohepatitis (SH).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of various iron deficiency criteria in patients with decompensated heart failure 失代偿性心力衰竭患者各种缺铁标准的预后价值
Clinical pharmacology and therapy Pub Date : 2023-11-04 DOI: 10.32756/0869-5490-2023-4-30-35
Z. Kobalava, A. Lapshin, S. Galochkin
{"title":"Prognostic value of various iron deficiency criteria in patients with decompensated heart failure","authors":"Z. Kobalava, A. Lapshin, S. Galochkin","doi":"10.32756/0869-5490-2023-4-30-35","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-4-30-35","url":null,"abstract":"To evaluate prognosis of hospitalized patients with decompensated heart failure (HF) and iron deficiency (ID) and the changes in ID occurrence without iron supplementation.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139289443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信